NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Matrivax Research & Development Corporation

Matrivax Research & Development Corporation

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://matrivax.com

Last Round

M&A

May 5, 2026

Total Funding Raised

$100,000

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Matrivax Research & Development Corporation is a biotechnology company that develops human vaccines and immunotherapeutics for the prevention and treatment of life-threatening bacterial diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyvaccine developmentprotein capsular matrix vaccinePCMVdrug discoveryimmunotherapeuticsbacterial vaccinesvaccine platformbiotech R&Dclinical-stage biotechbiotech licensingbiopharmavaccine techinfectious disease researchdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Matrivax Research & Development Corporation Comparables

Compare Matrivax Research & Development Corporation with similar companies based on industry and business-model similarity.

Matrivax Research & Development Corporation comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omniose
81%
Syntiron
77%
GSK plc
77%

Matrivax Research & Development Corporation Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMay 5, 2026
GrantNov 1, 2009
VC RoundOct 1, 2007

Matrivax Research & Development Corporation Investors

Notable investors and investment history

Matrivax Research & Development Corporation investors
InvestorRounds
Morningside VenturesVC Round
Bill & Melinda Gates FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2026

    Elaris FlexCo participated in the M&A round.

  • Nov 1, 2009

    $100K grant from Bill & Melinda Gates Foundation.

Matrivax Research & Development Corporation Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Matrivax Research & Development Corporation Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Matrivax Research & Development Corporation's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range5
Year Founded2007
Last FundingMay 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.